Editorial Comment
Receptor-Specific Antiplatelet Therapy Zaverio M. Ruggeri, MD C onsiderable progress has been made in recent years in understanding the molecular mechanisms involved in cell adhesion phenomena. In this regard, platelets represent a specialized circulating cell fragment, the main biological function of which is adhering to areas of vessel wall injury and aggregating with one another to form a hemostatic plug. Both adhesion and aggregation are mediated by the interaction of specific molecules with membrane glycoprotein receptors on the plate-See p 1775 let surface. Adhesion implies the attachment of platelets to molecules exposed as components of a thrombogenic surface, while aggregation involves the activity of soluble molecules bridging platelets to one another. During hemostasis, formation of the platelet plug occurs in concert with fibrin formation through activation of the coagulation system, and prothrombotic events are under the regulation of antiplatelet, anticoagulant, and fibrinolytic processes. Thus, hemostasis is a multifactorial, highly regulated mechanism that leads to the arrest of bleeding and the initiation of wound repair. It is important to contemplate the complexity of the hemostatic system when considering interventional procedures aimed at regulating its functions.
In pathologic conditions, unbalanced activity of components of the hemostatic system may be an important causative factor in occlusive vascular disease. If one considers ischemic heart disease, one of the most common morbidity and mortality factors in the developed world, as representing the epitome of occlusive arterial pathology, there is now significant evidence from clinical, histologic, and experimental studies that rupture of an atherosclerotic plaque with superimposed thrombosis occurs in the majority of patients with unstable angina, myocardial infarction, and sudden death of ischemic origin.1'2 Thrombi that form in diseased arteries are similar to hemostatic thrombi in their complexity. However, not only is the platelet component quantitatively predominant at the site of occlusion, at least in the early stages, but also there are reasons to assume that it represents the initial response to injury. Thus, blocking platelet adhesion and aggregation may have profound antithrombotic potential. It should not be expected to be efficacious in all instances, however, depending on the nature of the underlying pathology and the district of the vasculature in which the occlusion occurs, both of which factors influence thrombus composition. For example, it is assumed that fibrin clot formation is the leading cause in the pathogenesis of venous thrombosis.
The processes by which platelets are recruited at the site of injury include interaction of nonactivated platelets with surface adhesion molecules; activation of platelets by a variety of agonists, including athrombin, ADP, and collagen; and aggregation of activated platelets. It is noteworthy that adhesion may occur through multiple receptor-ligand interactions involving, for example, fibronectin, collagen, vitronectin, and von Willebrand factor as adhesive molecules, and distinct membrane binding sites. These various pathways of adhesion may operate under distinct, yet unrecognized, pathophysiologic conditions. Despite the multiple possibilities, however, von Willebrand factor binding to the GP Ib-IX complex appears to be essential for platelet adhesion when hemorrheologic conditions are dominated by high shear stress flow, similar to those found in coronary stenoses. 3 Thus, this interaction may be an important target for antithrombotic intervention. The same may be true for inhibition of thrombin generation because this active enzyme, the product of coagulation activation, appears to have a prominent role among agonists that activate platelets.4
One of the results of platelet activation is the functional expression of another platelet membrane receptor, the GP JIb-lIla complex, which may participate in adhesion events by binding to fibronectin, von Willebrand factor, and fibrinogen-fibrin, but whose main role is to mediate platelet-platelet contact (aggregation). Unlike adhesion, platelet aggregation appears to be essentially dependent on participation of this one receptor, potentially through interaction with four adhesive molecules-fibrin-ogen, von Willebrand factor, fibronectin, and vitronectin. Although fibrinogen is considered the physiologic GP lIb-lIla ligand, evidence is accumulating that von Willebrand factor is involved in mediating platelet aggregation under certain conditions, as suggested by ex vivo experiments. GP lIb-lIla, like many other platelet adhesion receptors with the notable exception of the GP Ib-IX complex, belongs to the large family of related molecules known as "integrins," whose common recognition site is the sequence Arg-Gly-Asp.5 Small molecules and synthetic peptides containing the integrin recognition sequence have been shown to inhibit GP lIb-lIla-mediated platelet functions by competing with the binding of physiologic ligands and, thus, have been considered as potential antithrombotic agents.
In this issue of Circulation, Haskel and co-workers6 present the results obtained in a canine experimental model using a peptide antagonist of GP lIb-lIla function for the prevention of femoral artery reocclusion after thrombolytic therapy. The antithrombotic effect was clear and comparable with that of aspirin when thrombolysis and thrombosis were assessed in the vascular-injury model, but both peptide and aspirin were markedly less effective in the copper wire-induced thrombosis model. The careful definition of thrombus composition in the two experimental conditions provides interesting confirmation of the concept that the choice of antithrombotic therapy must be based as much as possible on knowledge of the underlying pathogenetic conditions. Similarly, successes and failures of experimental studies should be carefully evaluated in view of the relevance of any given model to human thrombotic diseases, and, in this regard, the authors put their results in the correct perspective.
There are problems related to the use of peptides as antithrombotic agents. Their short survival time in the circulation may be advantageous in permitting rapid reversal of the antihemostatic effect in bleeding but certainly poses a burden in terms of the quantities needed for treatment. Transferring the experiments of Haskel and colleagues into animals with body masses equivalent to those of humans would have meant the use of up to 25.2 g peptide per infusion. Obviously, then, it is crucial to define compounds with greater affinity for the target platelet receptor and/or with better stability in vivo. In this regard, the compound used by Haskel et al is already fourfold more effective than peptides of similar size containing the sequence Arg-Gly-Asp-Ser found in physiologic GP JIb-lIla ligands. Moreover, studies are underway to exploit the high platelet affinity of naturally occurring polypeptides containing the integrin recognition sequence and present in snake venoms.7 Studies on the three-dimensional conformation of the Arg-Gly-Asp-containing domains in these molecules may provide important clues for designing compounds with improved GP lIb-IlIa-binding capacity. Another approach currently under investigation consists of substituting amino acid residues with organic groups to achieve better stability along with increased affinity and, eventually, the possibility of oral administration. Preliminary results have established the feasibility of such peptidomimetic compounds (personal observations in collaboration with Molino et al). In addition to efficacy, selectivity is also an important concern because integrin receptors are widely distributed and participate in many processes of biological relevance, including immune and other defense mechanisms. Thus, if antireceptor therapy is to develop into a long-term preventive antithrombotic strategy, selectivity for platelet receptors is an important goal to achieve.
Finally, antireceptor therapy to block platelet adhesive interactions should consider other targets in addition to GP JIb-lIla. Emphasis has been put recently on integrin receptors because of the significant progress made in understanding their molecular biology. Nevertheless, experimental considerations suggest that interfering with the von Willebrand factor-GP lb interaction may lead to inhibition of early platelet-surface adhesion events with prevention of activation and aggregation, particularly in vessels with flow characterized by high shear stress typical of diseased and stenosed arteries. One advantage of this approach is that it has inherent platelet specificity because GP lb appears to be an exclusive platelet receptor. Studies are currently being conducted to evaluate the potential antithrombotic efficacy of a family of genetically engineered compounds based on the recent definition of the GP lb-binding site in the von Willebrand factor molecule (personal observations in collaboration with Ricca et al). Significantly more work is indeed necessary to achieve the goal of selective antithrombotic therapy with specific inhibitors of platelet receptors. An array of compounds with distinct specificities should become available in the near future for extensive animal and clinical testing.
